ES2100164T3 - Deteccion y tratamiento de infecciones con inmunoconjugado. - Google Patents

Deteccion y tratamiento de infecciones con inmunoconjugado.

Info

Publication number
ES2100164T3
ES2100164T3 ES90309319T ES90309319T ES2100164T3 ES 2100164 T3 ES2100164 T3 ES 2100164T3 ES 90309319 T ES90309319 T ES 90309319T ES 90309319 T ES90309319 T ES 90309319T ES 2100164 T3 ES2100164 T3 ES 2100164T3
Authority
ES
Spain
Prior art keywords
antibody
diagnostic
antibodies
agent
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90309319T
Other languages
English (en)
Inventor
Milton David Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ES2100164T3 publication Critical patent/ES2100164T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL USO DE: (A) UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE A UN EPITOPE DE UNA ESPECIE SIMPLE DE PATOGENO O ANTIGENO DERIVADO DEL MISMO, O (B) UN COMPUESTO INMUNORREACTIVO DE UNA GRAN PLURALIDAD DE ANTICUERPOS O FRAGMENTOS DE ANTICUERPOS QUIMICAMENTE UNIDOS QUE SE UNEN A UNA PLURALIDAD DE EPITOPES DE UNA ESPECIE SIMPLE DE PATOGENO O ANTIGENO DERIVADO DEL MISMO; DICHO ANTICUERPO O FRAGMENTO DE ANTICUERPO O COMPUESTO SE CONJUGA CON AL MENOS UN AGENTE DIAGNOSTICO O TERAPEUTICO PARA FORMAR UN CONJUGADO DE ANTICUERPO; TAMBIEN SE REVELA, EN LA PREPARACION DE UN AGENTE PARA SU USO, UN METODO DE DIAGNOSIS O TERAPIA DE UN FOCO DE INFECCION, POR EL QUE A UN PACIENTE INFECTADO SE LE INYECTA DICHO CONJUGADO DE ANTICUERPO, DESTINANDO EL AGENTE DIAGNOSTICO O TERAPEUTICO CONJUGADO A DICHO FOCO, CON LO QUE SE CONSIGUE ASI SU FUNCION DIAGNOSTICA O TERAPEUTICA. TAMBIEN SE PROPORCIONA UNA PREPARACION ESTERIL INYECTABLE PARA TAL USO.
ES90309319T 1989-08-24 1990-08-24 Deteccion y tratamiento de infecciones con inmunoconjugado. Expired - Lifetime ES2100164T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39956689A 1989-08-24 1989-08-24

Publications (1)

Publication Number Publication Date
ES2100164T3 true ES2100164T3 (es) 1997-06-16

Family

ID=23580041

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90309319T Expired - Lifetime ES2100164T3 (es) 1989-08-24 1990-08-24 Deteccion y tratamiento de infecciones con inmunoconjugado.

Country Status (13)

Country Link
EP (1) EP0417927B1 (es)
JP (1) JPH07121880B2 (es)
KR (1) KR0179953B1 (es)
AT (1) ATE151994T1 (es)
AU (1) AU636172B2 (es)
CA (1) CA1339415C (es)
DE (1) DE69030545T2 (es)
ES (1) ES2100164T3 (es)
IE (1) IE903071A1 (es)
IL (1) IL95457A (es)
SG (1) SG46451A1 (es)
WO (1) WO1991002541A1 (es)
ZA (1) ZA906703B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
GB9517758D0 (en) * 1995-08-31 1995-11-01 Imutran Ltd Compositions and their uses
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
DE59907027D1 (de) * 1998-06-29 2003-10-23 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
JP4928964B2 (ja) 2007-01-30 2012-05-09 本田技研工業株式会社 車両のスイングアーム式懸架装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002522A1 (en) * 1980-03-03 1981-09-17 M Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
ATE61000T1 (de) * 1983-07-29 1991-03-15 Milton David Goldenberg Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.
US4855227A (en) * 1985-06-07 1989-08-08 Institute For Medical Research Rapid detection of mycoplasmas
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
CA1339857C (en) * 1987-05-29 1998-05-05 Cecily Rou-Yun Sun Monoclonal antibodies to gp120 which neutraleze hiv-1
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions

Also Published As

Publication number Publication date
IL95457A (en) 1997-01-10
DE69030545D1 (de) 1997-05-28
WO1991002541A1 (en) 1991-03-07
KR0179953B1 (ko) 1999-03-20
KR920700686A (ko) 1992-08-10
ATE151994T1 (de) 1997-05-15
AU6408290A (en) 1991-04-03
JPH07121880B2 (ja) 1995-12-25
CA1339415C (en) 1997-09-02
IL95457A0 (en) 1991-06-30
EP0417927A1 (en) 1991-03-20
JPH04506217A (ja) 1992-10-29
SG46451A1 (en) 1998-02-20
DE69030545T2 (de) 1997-08-07
IE903071A1 (en) 1991-02-27
ZA906703B (en) 1991-06-26
EP0417927B1 (en) 1997-04-23
AU636172B2 (en) 1993-04-22

Similar Documents

Publication Publication Date Title
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
NO964013D0 (no) Monoklonale antistoffer som gjenkjenner TIE-reseptor og deres anvendelse
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
AR005535A1 (es) El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2115618T3 (es) Uso de anticuerpos anti-icam en la preparacion de un medicamento para el tratamiento del choque por endotoxinas.
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
Fischel et al. The role of tubercle bacilli in adjuvant emulsions on antibody production to egg albumin
EA199900067A1 (ru) Очищенный поверхностный антиген сперматозоидов, моноклональное антитело для него и их применения
DK0470184T3 (da) Specifikke antistoffer for det CD4-bindende domæne i HIV
MX2024010334A (es) Composicion farmaceutica que comprende anticuerpo biespecifico anti-ctla4-anti-pd-1 y chiauranib.
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
ES2054667T3 (es) Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
IL95457A (en) Preparations containing immunoconjugates for detection and treatment of infections
EP0881910A4 (en) USE OF IMMUNOCONJUGATES TO ENHANCE THE EFFICACY OF MULTI-STEP VACCINES STIMULATING IMMUNE REACTIONS IN CASCADE
AR003941A1 (es) Anticuerpos monoclonales humanos neutralizadores de hiv-1
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
Sobh et al. Effect of anti-schistosomal treatment on schistosomal-specific nephropathy
Barnes Obstacles to an AIDS Vaccine: Human tests of AIDS vaccines proceed as researchers cape with setbacks from chimpanzee trials and grapple with fundamental questions about the virus
AR120389A1 (es) Un método para aumentar el recuento de linfocitos de células t cd4⁺ en un sujeto infectado con el virus de la inmunodeficiencia humana (vih)
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
ES2082962T3 (es) Medicamentos y metodos de tratamiento del sindrome de inmunodeficiencia adquirida (sida) y del complejo relacionado con el sida (arc) que utilizan anticuerpos anti-carbohidrato.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 417927

Country of ref document: ES